Literature DB >> 2642970

Possible role of human natural anti-Gal antibodies in the natural antitumor defense system.

V Castronovo1, C Colin, B Parent, J M Foidart, R Lambotte, P Mahieu.   

Abstract

Expression of Gal alpha 1-3Gal cell surface residues has been correlated with the metastatic potential of murine tumor cells. We report that Gal alpha 1-3Gal residues are expressed at the cell surface of malignant human cancer cells, including four cell lines and 50% of the malignant breast specimens obtained by aspiration biopsy. In contrast, all benign breast biopsies and normal cells were Gal alpha 1-3Gal negative. Affinity-purified anti-alpha-galactosyl IgG (anti-Gal) antibody, which specifically recognizes Gal alpha 1-3Gal residues, significantly inhibited cell attachment in two in vitro assays thought to indicate tumor cell extravasation of the circulatory system during the metastatic process: attachment to perfused human umbilical vein endothelium, and attachment to isolated laminin. Since anti-Gal antibody is a natural component of all human sera, we propose that it may be part of the natural antitumor defense system in humans.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2642970     DOI: 10.1093/jnci/81.3.212

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  15 in total

1.  Antibodies to mouse laminin in patients with systemic sclerosis (scleroderma) recognize galactosyl (alpha 1-3)-galactose epitopes.

Authors:  A Gabrielli; M Candela; A M Ricciatti; M L Caniglia; J Wieslander
Journal:  Clin Exp Immunol       Date:  1991-12       Impact factor: 4.330

2.  A monoclonal antibody for terminal beta-galactose. Use in analysis of glycosphingolipids.

Authors:  A Kalisiak; E Oosterwijk; J G Minniti; L J Old; D A Scheinberg
Journal:  Glycoconj J       Date:  1991-02       Impact factor: 2.916

3.  Natural human anti-Gal alpha(1,3)Gal antibodies react with human mucin peptides.

Authors:  M S Sandrin; H A Vaughan; P X Xing; I F McKenzie
Journal:  Glycoconj J       Date:  1997-01       Impact factor: 2.916

4.  Differential expression of an alpha-galactosyl-containing trisaccharide on high- and low-malignant murine sarcoma cells: identification and regulation.

Authors:  James Varani; Jerzy Petryniak; Masaru Takagaki; Michael K Dame; Bronislawa Petryniak; Irwin J Goldstein
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

5.  Localization of binding sites of Ulex europaeus I, Helix pomatia and Griffonia simplicifolia I-B4 lectins and analysis of their backbone structures by several glycosidases and poly-N-acetyllactosamine-specific lectins in human breast carcinomas.

Authors:  N Ito; S Imai; S Haga; C Nagaike; Y Morimura; K Hatake
Journal:  Histochem Cell Biol       Date:  1996-09       Impact factor: 4.304

6.  Subcellular distribution of terminal alpha-D- and beta-D-galactosyl residues in Ehrlich tumour cells studied by lectin-gold techniques.

Authors:  J Roth; I J Goldstein
Journal:  Glycoconj J       Date:  1995-04       Impact factor: 2.916

7.  Natural IgG antibody with anti-β-galactosyl specificity suppressed hepatoma cell invasion in culture.

Authors:  Yutaka Miura; Hiroshi Fujita; Fumihiko Sakai; Hiroyuki Tachikawa; Kazumi Yagasaki; Daisaburo Fujimoto
Journal:  Cytotechnology       Date:  2012-12-19       Impact factor: 2.058

8.  Cell surface laminin-like substances and laminin-related carbohydrates of rat ascites hepatoma AH7974 and its variants with different lung-colonizing potential.

Authors:  T Kawaguchi; T Ono; H Wakabayashi; S Igarashi
Journal:  Clin Exp Metastasis       Date:  1994-05       Impact factor: 5.150

9.  Monoclonal antibodies that recognize the trisaccharide epitope Gal alpha 1-3Gal beta 1-4GlcNAc present on Ehrlich tumor cell membrane glycoproteins.

Authors:  M Takagaki; R N Knibbs; J Roth; I J Goldstein
Journal:  Histochemistry       Date:  1993-08

Review 10.  Evolution and pathophysiology of the human natural anti-alpha-galactosyl IgG (anti-Gal) antibody.

Authors:  U Galili
Journal:  Springer Semin Immunopathol       Date:  1993
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.